RESHORING CASE

Arkopharma

Company details
Company name: 
Arkopharma
Company country: 
France
Sector: 
C - Manufacturing
Sector detail: 
C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Sub-sectors: 
C21.2.0 - Manufacture of pharmaceutical preparations
Reshoring details
Reshoring announcement date: 
10/04/2017
Starting implementation date: 
January, 2017
Reshored to: 
France
Location of affected unit(s): 
Carros
Location code: 
FRL0
Reshored business function: 
Production
Partial or Total reshoring: 
Total
Reshoring governance mode: 
In house (in own facilities)
Reasons for reshoring: 
"Made in" effect
Firm's global reorganization
R&D vicinity
Untapped production capacity
Case narrative: 

Arkopharma is a French pharmaceutical company founded in 1980 manufacturing phytotherapeutic and natural drugs and food integrators. In 2017, the company decided to to close its manufacturing sites in Italy and Ireland and centralize the production activities in Carros (France). The company aimed to reduce its production over-capacity increasing its efficiency level. It also aimed to leverage on the made in effect. Huge investments were implemented also to improve the collaboration between the R&D and the production departments.    

Sources: 

Marie Claire Méditerranées 07/12/2017

Arkopharma news

Offshoring details
Offshoring location: 
Italy
Offshored business function: 
Production
Offshoring governance mode: 
In house (in own facilities)
Host country geographical area: 
Western Europe